Trial Profile
A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults – version for European Union/United Kingdom sites
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms ACTT; ACTT I; ACTT-EU-UK; NIAID-ACTT
- 19 Jul 2023 Results published in the Journal of Infectious Diseases
- 29 Nov 2022 Results post hoc of analysis compared recovery and mortality between these comparable sequential cohorts of patients who received remdesivir plus SOC, adjusting for baseline characteristics with propensity score weighting published in the Annals of Internal Medicine
- 19 Aug 2021 Results(n=1051) assessing the dynamics of clinical progression changed along 4 pathways: recovery, improvement in respiratory therapy requirement, deterioration in respiratory therapy requirement, and death published in the Clinical Infectious Diseases